Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs
Abstract Background Decisions relating to the funding of new drugs are becoming increasingly challenging due to a combination of aging populations, rapidly increasing list prices, and greater numbers of drug-indication pairs being brought to market. This is especially true in cancer, where rapid lis...
Príomhchruthaitheoirí: | , , , , , , |
---|---|
Formáid: | Alt |
Teanga: | English |
Foilsithe / Cruthaithe: |
BMC
2019-07-01
|
Sraith: | BMC Public Health |
Ábhair: | |
Rochtain ar líne: | http://link.springer.com/article/10.1186/s12889-019-7303-2 |